期刊文献+

苦楝化学成分及抗糖尿病活性研究 被引量:4

Chemical Constituents from Melia azedarach and Their Anti-diabetes Activities
下载PDF
导出
摘要 为研究苦楝皮的化学成分及其抗糖尿病活性,采用正相、反相及Sephadex LH-20凝胶柱色谱等方法分离纯化化合物,通过波谱数据和理化性质分别鉴定为12β,20(S)-dihydroxydammar-24-en-3one(1),dammarendiol Ⅱ3-0-caffeate(2),24-methylenecyclosnenone(3),meliavolin(4),3,20-diacetyl-11-methoxy-1-tigloylmeliacarpinin(5),methyl3-formyl-2,4-dihydroxy-6.methylbenzoate(6),usnicacid(7),epi-catechin(8)。其中化合物1~3,6,7均为首次从该植物中分离得到。采用酶偶联、液闪接近测定等技术测试化合物2~5体外抗糖尿病活性。研究结果表明,受试化合物2~5均未表现出GK、SIRTl体外激动活性和DPPIV抑制活性,但化合物2对人11β-HSD1具有显著的抑制作用(IC50=94.15nmol/L)。 The chemical constituents from the barks of Melia azedarach were isolated by silica gel, reverse phase silica gel and Sephadex LH-20 column chromatography, and their anti-diabetes activities were subsequently evaluated. Eight compounds were obtained and elucidated as 12β,20 (S)-dihydroxydammar-24-en-3-one (1), dammarendiol II 3-O-caf- feate(2) ,24-methylenecycloartenone(3 ), meliav.olin (4) ,3,20-diacetyl-11-methoxy- 1-tigloylmeliacarpinin (5), methyl 3-formyl-2,4-dihydroxy-6-methyl benzoate (6), usnic acid (7) and epi-catechln (8) based on their spectra and physio- chemical characteristics. Among these, compounds 1-3,6, and 7 were isolated from this species for the first time. All the tested compounds 2-5 were inactive against GK, SIRT1 and DPPIV, but compounds 2 showed significant inhibitory activi- ty against human 11β-HSD1 with IC50 value of 94.15 nmol/L.
出处 《天然产物研究与开发》 CAS CSCD 北大核心 2014年第2期162-166,共5页 Natural Product Research and Development
基金 973计划前期研究专项(2011CB512005) 国家自然科学基金项目(81360477) 国家重点实验室培育基地-广西壮族自治区药用资源化学与药物分子工程重点实验室基金项目(CMEMR2012-B05) 2012年度广西高等学校优秀人才资助计划
关键词 苦楝 三萜 葡萄糖激酶 SIRT1 二肽基肽酶IV 11Β-羟基类固醇脱氢酶 Melia azedarach triterpenoids GK SIRT1 DPPIV 11β-HSD
  • 相关文献

参考文献10

  • 1汪建辉,欧瑜.葡萄糖激酶与糖尿病[J].药物生物技术,2012,19(6):552-556. 被引量:15
  • 2江慧贤,罗超,卢钧雄,曹莹,庞建新.构建二肽基肽酶-Ⅳ抑制剂体外筛选模型及相关化合物抑制活性的测定[J].中国实验方剂学杂志,2012,18(4):210-215. 被引量:4
  • 3李文斌,崔美玉,许冬梅,关广聚.二基肽酶Ⅳ酶活性与糖尿病肾病的相关性[J].山东大学学报(医学版),2010,48(3):12-14. 被引量:4
  • 4赵春超,王金辉,李文,沙沂,李铣.凤眼草的化学成分研究[J].中国药物化学杂志,2003,13(4):211-214. 被引量:16
  • 5Marc-Antoine Bazin,Anne-Cécile Le Lamer,Jean-Guy Delcros,Isabelle Rouaud,Philippe Uriac,Jo?l Boustie,Jean-Charles Corbel,Sophie Tomasi.Synthesis and cytotoxic activities of usnic acid derivatives[J].Bioorganic & Medicinal Chemistry.2008(14)
  • 6Simeon F. Kouam,Bonaventure T. Ngadjui,Karsten Krohn,Pascal Wafo,Asma Ajaz,M. Iqbal Choudhary.Prenylated anthronoid antioxidants from the stem bark of Harungana madagascariensis[J].Phytochemistry.2005(10)
  • 7U.L.B. Jayasinghe,H.S.K. Vithana,G.P. Wannigama,Y. Fujimoto.24-Methylenecycloartenone from Bhesa nitidissima[J].Fitoterapia.2001(5)
  • 8Koichi Takeya,Zhi-Sheng Qiao,Chieko Hirobe,Hideji Itokawa.Cytotoxic azadirachtin-type limonoids from Melia azedarach[J].Phytochemistry.1996(3)
  • 9Lu Zeng,Zhe-ming Gu,Xin-ping Fang,Phillip E Fanwick,Ching-jer Chang,David L Smith,Jerry L McLaughlin.Two new bioactive triterpenoids from Melia volkensii (Meliaceae)[J].Tetrahedron.1995(9)
  • 10Peter Waterman,Dalton Faulkner.(–)–Epiafzelechin from the Root Bark of Cassia sieberiana[J].Planta Med.1979(10)

二级参考文献74

  • 1林善锬.糖尿病肾病发病机制的几个关键[J].中华老年多器官疾病杂志,2002,1(3):165-167. 被引量:3
  • 2肖梅芳,张学梅,白香,谭焕然.不同糖尿病模型小鼠糖原代谢变化的研究[J].中国临床药理学与治疗学,2005,10(6):613-616. 被引量:22
  • 3涂晓文,陈香美.结缔组织生长因子:糖尿病肾病治疗的新靶点[J].国际泌尿系统杂志,2006,26(1):126-129. 被引量:1
  • 4欧阳礼枝,陆付耳,刘文军,高志强,徐丽君.小檗碱对胰岛素抵抗大鼠肝脏葡萄糖激酶及其调节蛋白的影响[J].世界华人消化杂志,2007,15(8):885-889. 被引量:17
  • 5Egawa S I, Watanabe Y, Kikuya Y, et al. Dipeptidyl pepfidase from human serum: purification, characterization, and N2 terminal aminoacid sequence [J].J Biochem, 1998, 124:428-433.
  • 6Patrick J Boyle, Jeffrey S. Application of incretin minmotics and dipeptidyl Peptidase IV inhibitors in managing type 2 diabetes mellitus [ J ]. JAOA, 2007 ( 107 ) : 10-16.
  • 7Daniel J. Dipeptikyl peptidase-4 inhibition and the treatment of type 2 diabetes [J].Diabetes Care, 2007, 30: 1335-1343.
  • 8Herman G A, stein P P, Thomberry N A, et al. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes : focus on sitagliptin [ J ]. Clinical Pharmacology and Therapeutics, 2007, 81:761-767.
  • 9Deacon C F, Hughes T E, Hoist J J. Dipeptidyl peptidase Ⅳ inhibition potentiates the insulinotropic effect of glucagons-like peptide 1 in the anesthetized pig [ J ]. Diabetes, 1998, 47:764-769.
  • 10Pederson R A, White H A, Schlenzig D, et al. Improved glucose tolerance in Zucker fatty rats by oral administra- tion of the dipeptidyl peptidase Ⅳ inhibitor isolercine thiazolidide[J]. Diabetes, 1998, 47 : 1253-1258.

共引文献34

同被引文献71

引证文献4

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部